TO TORNTPHARM
Torrent Pharmaceuticals Q2 2026
TOTORNTPHARM

Torrent Pharmaceuticals Q2 FY26 results (Jul–Sep 2025) and concall

Healthcare · Concall AI · Call held 7 Nov 2025

Management summary

  • Torrent Pharma delivered a robust Q2 FY26, driven by double-digit growth in its core branded markets of India and Brazil.
  • Despite supply disruptions in Germany, the company maintained strong operating margins at 32.8% and significantly reduced leverage.
  • Management is aggressively expanding its Indian field force and ramping up US ANDA filings to drive future growth.

Source: Inve concall analysis and management guidance record.

What they filed

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue2,377 2,433 2,616 2,762
EBITDA887 868 979 1,072
Net profit485 474 551 597
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Headcount

  • Field Force Strength Headcount · FY26 · High confidence 7,000

    From 6,800 today

Other

  • ANDA Filings Other · FY27 · Medium confidence 10

    From 4-5 today

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

1 direct
India Business Growth Drivers Direct
Breakup of volume is 3.7% versus 0% of the market. Price at 5.5% versus 5.5% of the market and new products at nearly 3% versus 2.5% of the market.

Reveals that Torrent is significantly outperforming the market on volume and new product launches, not just relying on price hikes.

Asked by Damayanti Kerai, HSBC

Germany Supply Disruption Partial
Right now, all indications are that to some extent will continue in Q3. Hopefully, Q4 onwards, it will not be the case.

Highlights a near-term headwind in the European business that is expected to persist for at least one more quarter.

Asked by Damayanti Kerai, HSBC

Unlock risks & concerns, Q3 FY26 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 3 risks, concerns & management red flags
  • Watchlist triggers for Q3 FY26
  • +3 more guidance targets & verbatim management quotes
  • +1 more analyst Q&A exchange & evasion checks
  • Full section-by-section call narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image